UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2152-8
Program Prior Authorization/Medical Necessity
Medication Orilissa® (elagolix)
P&T Approval Date 10/2018, 10/2019, 9/2020, 9/2021, 9/2022, 2/2023, 2/2024, 2/2025
Effective Date 5/1/2025
1. Background:
Orilissa (elagolix) is a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated
for the management of moderate to severe pain associated with endometriosis.
2. Coverage Criteriaa:
A. Orilissa 150 mg
1. Initial Authorization
a. Orilissa 150 mg will be approved based on all of the following criteria:
(1) Diagnosis of moderate to severe pain associated with endometriosis
-AND-
(2) Failure after a three-month trialb (e.g., inadequate pain relief), contraindication or
intolerance of two analgesics (e.g., ibuprofen, meloxicam, naproxen)
-AND-
(3) Failure after a three-month trialb, contraindication, or intolerance to one of the
following:
(a) Hormonal contraceptives
(b) Progestins [e.g., norethindrone (generic Aygestin®)]
-AND-
(4) Prescribed by or in consultation with one of the following:
(a) Obstetrics/Gynecologist (OB/GYN)
(b) Reproductive endocrinologist
Authorization will be issued for 12 months
2. Reauthorization
a. Orilissa 150 mg will be approved based on all of the following criteria:
© 2025 UnitedHealthcare Services Inc.
1
(1) Documentation of positive clinical response to therapy
(2) Impact to bone mineral density has been considered
(3) Treatment duration has not exceeded a total of 24 months
Authorization will be issued for 12 months up to a maximum treatment duration of 24
months
NOTE: Orilissa 150 mg once daily is indicated for a maximum treatment duration of 24
months
B. Orilissa 200 mg
1. Initial Authorization
a. Orilissa 200 mg will be approved based on all of the following criteria:
(1) Diagnosis of moderate to severe pain associated with endometriosis
-AND-
(2) Failure after a three-month trialb (e.g., inadequate pain relief), contraindication or
intolerance of two analgesics (e.g., ibuprofen, meloxicam, naproxen)
-AND-
(3) Failure after a three-month trialb, contraindication, or intolerance to one of the
following:
(a) Hormonal contraceptives
(b) Progestins [e.g., norethindrone (generic Aygestin)]
-AND-
(4) Prescribed by or in consultation with one of the following:
(a) Obstetrics/Gynecologist (OB/GYN)
(b) Reproductive endocrinologist
Authorization will be issued for 6 months
NOTE: Orilissa 200 mg twice daily is indicated for a maximum treatment duration of 6
months
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
b For Connecticut, Kentucky and Mississippi business, only a 30 day trial will be required.
© 2025 UnitedHealthcare Services Inc.
2
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Orilissa [package insert]. North Chicago, IL: AbbVie Inc.; June 2023.
2. Taylor H, Giudice L, Lessey B, et al. Treatment of endometriosis-associated pain with
elagolix, an oral GnRH antagonist. N Engl J Med 2017; 377:28-40.
3. The American College of Obstetricians and Gynecologists. Management of endometriosis.
Practice Bulletin 114. July 2010 (Reaffirmed 2018).
Program Prior Authorization/Medical Necessity – Orilissa
Change Control
Date Change
10/2018 New program
10/2019 Annual review. No changes.
9/2020 Annual review. Updated references.
9/2021 Annual review. Updated CT and KY trial language. Updated references.
9/2022 Annual review. Updated mandate language to include Mississippi.
2/2023 Removed the criteria that patient is premenopausal.
2/2024 Annual review. Updated failure language. Updated state mandate
language. Updated authorization duration. Updated references.
2/2025 Annual review. No changes.
© 2025 UnitedHealthcare Services Inc.
3